Changes in HIV-1 Subtypes/Sub-Subtypes,and Transmitted Drug Resistance Among ART-Naïve HIV-Infected Individuals—China,2004–2022  

作　　者：Xiu Liu Dong Wang Jing Hu Chang Song Lingjie Liao Yi Feng Dan Li Hui Xing Yuhua Ruan 

机构地区：[1]State Key Laboratory of Infectious Disease Prevention and Control(SKLID),National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention(China CDC),Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,Beijing,China.

出　　处：《China CDC weekly》2023年第30期664-671,I0010-I0012,共11页中国疾病预防控制中心周报（英文）

基　　金：Supported by the Ministry of Science and Technology of China(grant numbers 2022YFC2305205,2022YFC2305201);the National Natural Science Foundation of China(grant number 82260670);Guangxi Bagui Honor Scholarship;and Chinese State Key Laboratory of Infectious Disease Prevention and Control.

摘　　要：Introduction:The efficacy of treatment and clinical outcomes may be jeopardized by factors such as transmitted drug resistance(TDR)and the genetic diversity of the human immunodeficiency virus type 1(HIV-1).This comprehensive study aims to examine the alterations in HIV-1 subtypes or sub-subtypes and TDR among Chinese individuals,who have been diagnosed with HIV infection and are previously untreated with antiretroviral therapy(ART),across the span of 2004 to 2022.Methods:Sequences of the HIV-1 pol gene region were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.To predict susceptibility to 12 antiretroviral drugs,the research utilized the Stanford HIV Drug Resistance Database.The Cochran-Armitage trend test facilitated the analysis of changes in HIV-1 subtype/sub-subtype prevalence and TDR.This analysis was conducted in alignment with the progression of the National Free Antiretroviral Treatment Program’s stages between 2004 and 2022.Results:Among the 57,902 ART-naïve individuals infected with HIV,there was a notable decline in the prevalence of CRF01_AE,B,and C from 37.3%,24.1%,and 1.3%respectively in 2004–2007 to 29.4%,7.3%,and 0.2%respectively in 2020–2022.Simultaneously,a significant increase was observed in the proportions of CRF07_BC,CRF08_BC,CRF55_01B,other CRFs,and URFs,from 24.1%,11.5%,0.1%,0.4%,and 0.9%respectively in 2004–2007 to 40.8%,11.5%,3.8%,3.7%,and 2.8%respectively in 2020–2022(all P<0.001 for trend).The prevalence of TDR to overall,non-nucleoside reverse transcriptase inhibitor(NNRTI),efavirenz,and nevirapine also significantly increased from 2.6%,1.8%,1.6%,and 1.8%respectively in 2004–2007 to 7.8%,6.7%,6.3%,and 6.7%respectively in 2020–2022(all P<0.001 for trend).However,there were no meaningful changes in the TDR prevalence of nucleoside reverse transcriptase inhibitor and protease inhibitor.Notably,in 2020–2022,the overall TDR prevalence exceeded 15%in Xinjiang.Conclusions:The total prevalence of TD

关 键 词：PREVALENCE alterations DRUGS 

分 类 号：R512.91[医药卫生—内科学]